[Federal Register Volume 74, Number 1 (Friday, January 2, 2009)]
[Page 110]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E8-31187]



Food and Drug Administration

[Docket No. FDA-2008-N-0038]

Blood Products Advisory Committee; Notice of Meeting; Amendment

AGENCY:  Food and Drug Administration, HHS

ACTION:  Notice.


    The Food and Drug Administration (FDA) is announcing an amendment 
to the notice of the Blood Products Advisory Committee. This meeting 
was announced in the Federal Register of December 9, 2008 (73 FR 
74725). The amendment is being made to reflect a change in the Agenda 
portion of the document.

FOR FURTHER INFORMATION CONTACT: Contact Person: William Freas or 
Pearline K. Muckelvene, Center for Biologics Evaluation and Research 
(HFM-71), Food and Drug Administration, 1401 Rockville Pike, Rockville, 
MD 20852, 301-827-0314, or FDA Advisory Committee Information Line, 1-
800-741-8138 (301-443-0572 in the Washington, DC area), code 
3014519516. Please call the Information Line for up-to-date information 
on this meeting. A notice in the Federal Register about last minute 
modifications that impact a previously announced advisory committee 
meeting cannot always be published quickly enough to provide timely 
notice. Therefore, you should always check the agency's Web site and 
call the appropriate advisory committee hot line/phone line to learn 
about possible modifications before coming to the meeting.

SUPPLEMENTARY INFORMATION: In the Federal Register of December 9, 2008, 
FDA announced that a meeting of the Blood Products Advisory Committee 
would be held on January 9, 2009. On page 74725, in the first column, 
in the 13th line of the Agenda portion of the document, after the 
phrase ``Acid Constructs'' the following has been added:
    ``Included in the update will be an overview of the Center of 
Veterinary Medicine's review of the new animal drug application 
pertaining to the genetically engineered animals producing milk that 
contains recombinant Antithrombin III and of the environmental 
assessment for that application.''
    This notice is issued under the Federal Advisory Committee Act (5 
U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.

    Dated: December 24, 2008.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E8-31187 Filed 12-29-08; 11:15 am]